By FieldPulse Editorial · March 18, 2026
Tags: rare-disease, field-force, argenx
argenx now has FDA approval across gMG, CIDP, and ITP, creating overlapping rep coverage and quota complexity. The company released new territory alignment protocols in Q1 2026.
argenx has received FDA approvals for efgartigimod (Vyvgart) across three distinct indications — generalized myasthenia gravis (gMG), chronic inflammatory demyelinating polyneuropathy (CIDP), and immune thrombocytopenia (ITP) — with a fourth indication in bullous pemphigoid under FDA review as of early 2026. The multi-indication expansion has created a complex field structure in which some reps carry overlapping patient populations across neurology and hematology. For reps hired into the gMG franchise in 2022 and 2023, the CIDP and ITP approvals have brought both opportunity and organizational